Investigator

Hongbing Shen

Leading Scholar · University of California Los Angeles, School of Public Health

HSHongbing Shen
Papers(1)
Identification of Rec…
Collaborators(3)
Jiaping ChenJuncheng DaiZhibin Hu
Institutions(1)
State Key Laboratory …

Papers

Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population

BRCA1 and BRCA2 as important DNA repair genes have been thoroughly investigated in abundant studies. The potential relationships of BRCA1/2 pathogenic variants between multicancers have been verified in Caucasians but few in Chinese. In this study, we performed a two‐stage study to screen BRCA1/2 pathogenic variants or variants of uncertain significance (VUS) with 7580 cancer cases and 4874 cancer‐free controls, consisting of a discovery stage with 70 familial breast cancer cases and a subsequent validation stage with 7510 cases (3217 breast cancer, 1133 cervical cancer, 2044 hepatocellular carcinoma, and 1116 colorectal cancer). 48 variants were obtained from 70 familial breast cancer cases after BRCA1/2 exon detection, and finally, 20 pathogenic variants or VUS were selected for subsequent validation. Four recurrent variants in sporadic cases (BRCA1 c.4801A>T, BRCA1 c.3257del, BRCA1 c.440del, and BRCA2 c.7409dup) were identified and three of them were labeled Class 5 by ENIGMA. Two variants (BRCA1 c.3257del and c.440del) were specific in breast cancer cases, while BRCA2 c.7409dup and c.4307T>C were detected in two hepatocellular carcinoma patients and the BRCA1 c.4801A>T variant in one cervical cancer patient, respectively. Moreover, BRCA1 c.3257del was the most frequent variant observed in Chinese sporadic breast cancer and showed increased proliferation of BRCA1c.3257del‐overexpressing triple‐negative breast cancer cell lines (MDA‐MB‐231) in vitro. In addition to the known founder deleterious mutations, our findings highlight that the recurrently pathogenic variants in breast cancer cases could be taken as candidate genetic screening loci for a more efficient genetic screening of the Chinese population.

326Works
1Papers
3Collaborators

Positions

2015–

Leading Scholar

University of California Los Angeles · School of Public Health

2015–

Fellow

Royal College of Physicians · School of Public Health

2002–

Professor of Epidemiology

Nanjing Medical University · Epidemiology & Biostatistics

2018–

Adjunct Professor

The Chinese University of Hong Kong · The Jockey Club School of Public Health and Primary Care

2001–

Instructor

The University of Texas M. D. Anderson Cancer Center · Epidemiology

1999–

Visiting scientist

The University of Texas M. D. Anderson Cancer Center · Epidemiology

1998–

Associate Professor

Nanjing Medical University · Epidemiology & Biostatistics

1992–

Epidemiology & Biostatistics

Nanjing Medical University · Epidemiology & Biostatistics

Education

1999

Ph.D.

Fudan University · Epidemiology

1989

M.Sc.

Nanjing Medical University · Epidemiology

1986

Medical Diploma

Nanjing Medical University · Public Health

Country

CN

Links & IDs
0000-0002-2581-5906

Scopus: 7404522651